Trial Profile

An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long Term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants with Bullous Pemphigoid

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 28 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Efgartigimod alfa (Primary) ; Prednisone (Primary)
Indications Bullous pemphigoid
Focus Adverse reactions; Registrational
Acronyms BALLAD+
Sponsors argenx

Most Recent Events

23 Apr 2025 Status changed from active, no longer recruiting to discontinued.
11 Oct 2024 Status changed from recruiting to active, no longer recruiting.
08 Sep 2023 Planned End Date changed from 6 Nov 2025 to 6 Mar 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com